Preston Eibling, DO
Neuromuscular Medicine · Dublin, OHNPI 1558723072
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,388 of the $15,283 with a category attached, or 87.6%. AstraZeneca accounts for 97.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $8,476 and has fallen 98.7% since, to $114 in 2025.
Across 23 payments — averaging $664.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- UCB, Inc.$125
- Argenx US, Inc.$109
- Sanofi$77
- Catalyst Pharmaceuticals, Inc.$33
What the payments were for
- Speaking & faculty fees$13,38888%
- Travel & lodging$8606%
- Food & beverage$9156%
- Education$1211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $14,939 |
| UCB, Inc. | 1 | $125 |
| Argenx US, Inc. | 1 | $109 |
| Sanofi | 1 | $77 |
| Catalyst Pharmaceuticals, Inc. | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 25 | $46,013 |
| UbrelvyUbrogepant | 12 | $10,673 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,400 |
| Gabapentin | 227 | $3,098 |
| Riluzole | 23 | $2,846 |
| Pregabalin | 57 | $2,235 |
| Memantine Hcl | 156 | $2,070 |
| Oxcarbazepine | 39 | $1,776 |
| Donepezil Hcl | 139 | $1,704 |
| Mycophenolate Mofetil | 23 | $1,459 |
| Pyridostigmine Bromide | 19 | $1,453 |
| Propranolol Hcl ErPropranolol Hcl | 62 | $1,375 |
| Azathioprine | 34 | $1,315 |
| Duloxetine Hcl | 36 | $959 |
| Levetiracetam | 49 | $919 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Dublin
- Komal SawlaniCleveland$2K
- Robert AdamsCleveland$572
- Preetha MuthusamyWarren$521
- Georgette DibCleveland$445
- Christelle HaddadCleveland$220
- Benjamin ClaytorCleveland$211
- Alexander MorrisonColumbus$200
- Danielle RichardsCleveland$156
- Robert MarquardtCleveland$154
- Mahmood ShbebCleveland$154
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.